Francesca Pistoia

L'aquila, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 166 publications

Correction: Real‑World Response and Super‑Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Correction: Real‑World Response and Super‑Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Journal: Neurology and therapy

Published: July 23, 2026

SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study).

SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study).

Journal: Cephalalgia : an international journal of headache

Published: June 26, 2026

Effectiveness of Onabotulinumtoxin-A in Patients with Chronic Migraine and Previous CGRP-mAb Treatment Failure: A Multicentre 6-Month Real-World Experience.

Effectiveness of Onabotulinumtoxin-A in Patients with Chronic Migraine and Previous CGRP-mAb Treatment Failure: A Multicentre 6-Month Real-World Experience.

Journal: Toxins

Published: June 01, 2026

Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.

Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.

Journal: The journal of headache and pain

Published: May 10, 2026

The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability.

The chronopharmacology of atogepant in migraine prevention: A real-world evaluation of influence of timing of administration on effectiveness and tolerability.

Journal: Cephalalgia : an international journal of headache

Published: March 25, 2026

Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study.

Journal: Neurology and therapy

Published: March 18, 2026

Clinical outcomes at 6 months after MRgFUS thalamotomy in Parkinson's disease: a large longitudinal cohort study.

Clinical outcomes at 6 months after MRgFUS thalamotomy in Parkinson's disease: a large longitudinal cohort study.

Journal: Journal of neurology

Published: March 16, 2026

Innovative treatments for migraine: a new era.

Innovative treatments for migraine: a new era.

Journal: Therapeutic advances in neurological disorders

Published: March 12, 2026

Translation and validation of the Migraine Interictal Burden Scale (MIBS-4) in an Italian clinical cohort.

Translation and validation of the Migraine Interictal Burden Scale (MIBS-4) in an Italian clinical cohort.

Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Published: March 07, 2026

Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study).

Levels of migraine controls following International Headache Society (IHS) recommendations with eptinezumab: Effectiveness and tolerability in a 24-week, prospective multicenter study (the TACHIS study).

Journal: Cephalalgia : an international journal of headache

Published: February 13, 2026

Sex Differences in Levodopa-Sparing Effect of Safinamide: Post-hoc Findings from a Multicenter, Longitudinal, Case-Control Study.

Sex Differences in Levodopa-Sparing Effect of Safinamide: Post-hoc Findings from a Multicenter, Longitudinal, Case-Control Study.

Journal: Movement disorders clinical practice

Published: January 12, 2026

Rapid effectiveness of eptinezumab to treat ongoing migraine attacks: preliminary data from an Italian multicenter real-world experience (the BE-FREE study).

Rapid effectiveness of eptinezumab to treat ongoing migraine attacks: preliminary data from an Italian multicenter real-world experience (the BE-FREE study).

Journal: Frontiers in neurology

Published: January 09, 2026

Showing 1-12 of 166

Last Updated: 09/26/2026